[go: up one dir, main page]

WO2006082597A3 - Crystal modification of 5-substituted-2-oxazoiidone derivative and its process thereof - Google Patents

Crystal modification of 5-substituted-2-oxazoiidone derivative and its process thereof Download PDF

Info

Publication number
WO2006082597A3
WO2006082597A3 PCT/IN2006/000024 IN2006000024W WO2006082597A3 WO 2006082597 A3 WO2006082597 A3 WO 2006082597A3 IN 2006000024 W IN2006000024 W IN 2006000024W WO 2006082597 A3 WO2006082597 A3 WO 2006082597A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazoiidone
derivative
substituted
crystal modification
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000024
Other languages
French (fr)
Other versions
WO2006082597A2 (en
Inventor
Mohan Anand Chandavarkar
Rajaram Uday Bapat
Vivek Manohar Khare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FDC Ltd
Original Assignee
FDC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FDC Ltd filed Critical FDC Ltd
Publication of WO2006082597A2 publication Critical patent/WO2006082597A2/en
Publication of WO2006082597A3 publication Critical patent/WO2006082597A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses crystalline Polymorphic Form I of compound 5-(3,5- dimethylphenoxy-) methyl)-2-oxazolidinone, characterized by x-ray diffraction pattern having peaks at 10.355, 14.285,18.625, 19.030, 20.810 and 22.475± 0.30 degrees 2 theta angle, and melting point ranging from 122.50C to 1240C which is characterized by Diffrencial Scanning Calorimetry. The present invention further discloses processes for the preparation thereof, pharmaceutical preparations comprising the said Polymorph and its use in the treatment of depression of central synaptic transmissions.
PCT/IN2006/000024 2005-01-24 2006-01-24 Crystal modification of 5-substituted-2-oxazoiidone derivative and its process thereof Ceased WO2006082597A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN71/MUM/2005 2005-01-24
IN71MU2005 2005-01-24

Publications (2)

Publication Number Publication Date
WO2006082597A2 WO2006082597A2 (en) 2006-08-10
WO2006082597A3 true WO2006082597A3 (en) 2006-12-21

Family

ID=36777616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000024 Ceased WO2006082597A2 (en) 2005-01-24 2006-01-24 Crystal modification of 5-substituted-2-oxazoiidone derivative and its process thereof

Country Status (1)

Country Link
WO (1) WO2006082597A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007074477A2 (en) * 2005-12-29 2007-07-05 Dabur Pharma Limited Metaxalone polymorphs
US20090163561A1 (en) * 2007-12-21 2009-06-25 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062827A (en) * 1959-06-19 1962-11-06 Robins Co Inc A H 5-(3', 5'-dialkylphenoxymethyl)-2-oxazolidones
US3446814A (en) * 1965-07-24 1969-05-27 Henkel & Cie Gmbh Process for the preparation of substituted oxazolidones
WO2003061552A2 (en) * 2002-01-14 2003-07-31 Sun Pharmaceutical Industries Limited Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062827A (en) * 1959-06-19 1962-11-06 Robins Co Inc A H 5-(3', 5'-dialkylphenoxymethyl)-2-oxazolidones
US3446814A (en) * 1965-07-24 1969-05-27 Henkel & Cie Gmbh Process for the preparation of substituted oxazolidones
WO2003061552A2 (en) * 2002-01-14 2003-07-31 Sun Pharmaceutical Industries Limited Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone

Also Published As

Publication number Publication date
WO2006082597A2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
JP2008518904A5 (en)
EP2457918A3 (en) Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
WO2009080226A3 (en) Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP2007016035A5 (en)
WO2009149139A8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009050242A3 (en) Heterocycle-substituted piperazino-dihydrothienopyrimidines
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
RU2013138733A (en) CONDENSED AMINODIHYDROTHIAZINE DERIVATIVES
JP2006514626A5 (en)
WO2009068170A3 (en) 2-(benzyl- and 1h-pyrazol-4-ylmethyl)sulfinyl thiazole derivatives as herbicides and plant growth regulators
WO2005095379B1 (en) Crystalline methanesulfonic acid addition salts of imatinib
WO2010067374A3 (en) Polymorphs of dasatinib
WO2008115999A8 (en) Biaryl and biheteroaryl compounds useful in treating iron disorders
WO2004096800A3 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
WO2009070314A3 (en) Crystalline form of sitagliptin
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
WO2009047802A3 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2008011110A3 (en) Di-amino-substituted heterocyclic compounds and methods of use
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
WO2007041077A3 (en) Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06728386

Country of ref document: EP

Kind code of ref document: A2